TG Therapeutics (TGTX) Alert: Johnson Fistel Investigates TG Therapeutics, Inc.; Investors Encouraged to Contact the Firm

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Johnson Fistel, LLP, a shareholder rights law firm, is investigating potential claims on behalf of investors of TG Therapeutics, Inc. (NASDAQ: TGTX) ("TG Therapeutics"). TG Therapeutics is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. [click here to join this action]

On September 26, 2018, TG Therapeutics closed down over 44% to close at $5.15. The price decline followed TG Therapeutics' announcement that it could not proceed with the interim analysis of UNITY-CLL as a result of the Data Safety Monitoring Board trials. These trials determined that the trial data was not mature enough to continue. 

If you are a shareholder who suffered a loss and are interested in learning more about your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If you email, please include your phone number.

Additionally, you may [click here to join this action].There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[click here to join this action]

SOURCE Johnson Fistel, LLP